FDA Rescinds Turning Point Brands’ Marketing Denial Orders


“We are encouraged by the FDA’s decision to reconsider our product applications and look forward to engaging the agency as our PMTAs are reviewed,” said Larry Wexler, President and CEO, Turning Point Brands. “It is important that the PMTA process is transparent, purposeful, and evidence-based. Our organization dedicated significant time and resources in filing our applications in accordance with agency guidance. We remain hopeful that the depth and range of our studies and data will persuade the FDA that the continued marketing of our vapor products is appropriate for the protection of the public health and that the agency will ultimately preserve a diverse vapor market for the more than 30 million American adult smokers who may wish to transition from combustible cigarettes to lower risk alternatives.”

Because of the FDA’s action, the agency will continue to review Turning Point Brands’ proprietary vapor products, which will continue to marketed during the review period.

For all the latest news from Turning Point Brands, visit turningpointbrands.com.